Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Open Access
- 16 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (7), 2110-2120
- https://doi.org/10.1007/s00259-020-05156-4
Abstract
Purpose In 2017, the Geneva Alzheimer’s disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatability of the second-generation tau PET tracers into the clinical context. Methods All available literature was systematically searched based on a set of search terms that related independently to analytic validity (phases 1–2), clinical validity (phase 3–4), and clinical utility (phase 5). The progress on each of the phases was determined based on scientific criteria applied for each phase and coded as fully, partially, preliminary achieved or not achieved at all. Results The validation of the second-generation tau PET tracers has successfully passed the analytical phase 1 of the strategic biomarker roadmap. Assay definition studies showed evidence on the superiority over first-generation tau PET tracers in terms of off-target binding. Studies have partially achieved the primary aim of the analytical validity stage (phase 2), and preliminary evidence has been provided for the assessment of covariates on PET signal retention. Studies investigating of the clinical validity in phases 3, 4, and 5 are still underway. Conclusion The current literature provides overall preliminary evidence on the establishment of the second-generation tau PET tracers into the clinical context, thereby successfully addressing some methodological issues from the tau PET tracer of the first generation. Nevertheless, bigger cohort studies, longitudinal follow-up, and examination of diverse disease population are still needed to gauge their clinical validity.Keywords
Funding Information
- Projekt DEAL
This publication has 58 references indexed in Scilit:
- Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary TanglesJournal of Nuclear Medicine, 2016
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaThe Lancet Neurology, 2014
- Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic ConsiderationsJournal of Nuclear Medicine, 2013
- Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of agingNeurobiology of Aging, 2010
- 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain, 2008
- Natural history of mild cognitive impairment in older personsNeurology, 2002
- Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer DiseaseAmerican Journal of Geriatric Psychiatry, 2002
- Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer DiseaseAmerican Journal of Geriatric Psychiatry, 2002
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984